Detalles de la búsqueda
1.
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy.
Cancer Immunol Immunother
; 73(2): 21, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38279995
2.
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.
Br J Haematol
; 200(1): 64-69, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36155897
3.
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.
Int J Mol Sci
; 23(18)2022 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36142281
4.
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Br J Cancer
; 120(5): 527-536, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723303
5.
Veliparib: a new therapeutic option in ovarian cancer?
Future Oncol
; 15(17): 1975-1987, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31074636
6.
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Int J Mol Sci
; 20(11)2019 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31212634
7.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Lancet Oncol
; 19(10): 1360-1371, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30217671
8.
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Mol Cancer
; 16(1): 86, 2017 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28454547
9.
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Biol Blood Marrow Transplant
; 23(3): 459-466, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28039079
10.
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.
Mol Med
; 23: 235-246, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28805233
11.
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Lancet Oncol
; 16(1): 98-107, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25498219
12.
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
BMC Cancer
; 15: 374, 2015 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25952930
13.
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets.
Expert Opin Ther Targets
; 28(1-2): 17-28, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38234142
14.
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective.
Cancers (Basel)
; 16(1)2023 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38201531
15.
Baseline Values of Circulating IL-6 and TGF-ß Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment.
Cancers (Basel)
; 15(21)2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37958430
16.
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages.
Mol Oncol
; 17(8): 1474-1491, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183363
17.
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade.
Clin Cancer Res
; 2023 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992307
18.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Cancers (Basel)
; 15(4)2023 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36831376
19.
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
Clin Cancer Res
; 29(3): 621-634, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36165915
20.
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
J Exp Clin Cancer Res
; 42(1): 310, 2023 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37993874